Drugs / ZA-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06359821 | May → Oct 2024 | metastatic prostate carcinoma | Sichuan University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZA-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06359821 ↗ |
| Modality | Other / unclassified | “an Alpha-particle-emitting (At211) Radiopharmaceutical” NCT06359821 ↗ |
| Route | Intravenous | “administered via intravenous injection” NCT06359821 ↗ |